Arlin Davila, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Farmacia San Antonio, 149 Tierra Santa, Villalba, PR 00766 Phone: 787-847-1096 |
Maryann Santiago, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Farmacia San Antonio, 149 Tierra Santa, Villalba, PR 00766 Phone: 787-847-1096 |
Maria Tirado, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: Farmacia San Antonio, 149 Tierra Santa, Villalba, PR 00766 Phone: 787-847-1096 |
Lizbeth Barrios, Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 149 Tierra Santa, Farmacia San Antonio, Villalba, PR 00766 Phone: 787-847-1096 |
News Archive
Estill Medical Technologies, Inc., a family-owned Texas company that produces the Thermal Angel Blood and IV Fluid Infusion Warmer, a patented medical device being utilized by U.S. hospitals, military and emergency responders to lessen the effects of fluid-induced hypothermia, named the CALSTAR 6 Unit of South Lake Tahoe as the first-ever recipient of their "Thermal Angel Lifesaver of the Year Award."
Scientists at Columbia University's Mailman School of Public Health, the South African National Institute for Communicable Diseases of National Health Laboratory Service (NICD-NHLS), the U.S. Centers for Disease Control and Prevention, and Roche's 454 Life Sciences Corporation have discovered the new virus responsible for a highly fatal hemorrhagic fever outbreak in Zambia and South Africa in late 2008.
Your immune system plays an important function in your health - it protects you against viruses, bacteria, and other toxins that can cause disease. In autoinflammatory diseases, however, the immune system goes awry, causing unprovoked and dangerous inflammation.
Women who have experienced multiple forms of violence, from witnessing neighborhood crimes to being abused themselves, are more likely to engage in risky sexual behavior, according to a new report in the Psychology of Violence.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 5 days ago